AMG.DE - Amgen Inc.

XETRA - XETRA Delayed price. Currency in EUR
176.56
-0.20 (-0.11%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous close176.76
Open175.58
Bid0.00 x 20000
Ask0.00 x 9000
Day's range175.10 - 176.92
52-week range148.00 - 190.72
Volume630
Avg. volume1,023
Market cap105.521B
Beta (3Y monthly)0.22
PE ratio (TTM)14.02
EPS (TTM)12.60
Earnings dateN/A
Forward dividend & yield5.26 (2.97%)
Ex-dividend date2019-08-14
1y target estN/A
  • Better Buy: Amgen vs. Celgene
    Motley Fool

    Better Buy: Amgen vs. Celgene

    Which stock wins in a battle between these two big biotechs?

  • Motley Fool

    Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy

    Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.

  • 4 Biotech Stocks With Big Catalysts in September
    Motley Fool

    4 Biotech Stocks With Big Catalysts in September

    Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.

  • Here's Why Alexion Pharmaceuticals Dropped 11% in August
    Motley Fool

    Here's Why Alexion Pharmaceuticals Dropped 11% in August

    It was a roller coaster of a month for the biotech.

  • Amgen’s ‘White Whale’ Cancer Data May Send Shares to Record High
    Bloomberg

    Amgen’s ‘White Whale’ Cancer Data May Send Shares to Record High

    (Bloomberg) -- Amgen Inc. shares could hit a record if an experimental new cancer medicine is able to show improvements in a handful of patients later this week.A medicine known as AMG 510 has already shown early promise as data from June indicated the treatment can lead to responses at low doses. AMG 510 targets a cancer mutation known as KRAS G12C, which is thought to be present in roughly 13% of non-small cell lung and as many as 5% of colon tumors.Getting a drug to work on KRAS mutations has been the “the white whale of drug discovery,” Amgen’s head of global development has said.Updated results for AMG 510 are expected to be presented at the International Association for the Study of Lung Cancer or IASLC’s World Conference on Lung Cancer in Barcelona on Sunday. Options data for Amgen implies the stock may move 3.6% either way between now and Sept. 13. A more than 3% move to the upside for the biotech company would drive shares to a record high.According to one of the more bullish analysts covering Amgen - Jefferies’ Michael Yee - Medicines targeting KRAS have the potential to be a $2 billion or more class of drugs. Yee expects the data to show three more months of follow-up for the initial 5 of 10 lung cancer patients who responded to the therapy.Investors are looking for an overall response rate of 50% or better for the higher dose of the drug, Yee said. That’s after the lung cancer data showed that all three lung cancer patients getting the highest dose had responded in the last update. He expects the next look at the data may be in ten to 15 patients, although the company hasn’t guided as to how many patients will be in those results.Seventy-five percent or better would be a bull case, but even if the response rate were below 50%, Amgen still has a drug, Yee said. However, that could open the door for a key competitor, smallcap drug developer Mirati Therapeutics Inc.The next 12 months for Amgen will be “catalyst packed” Yee said. With less hedge funds and mutual funds invested in Amgen than other large-cap biotech peers, Amgen has room for those investors to come into the name, he told clients in an August video.Amgen bears have eyed the company’s early data and speculated Mirati’s competing medicine could produce better results. The small-cap’s shares rose 8 fold from the start of 2017 through 2018. Yet, there are signs the mania may be fading. A scant month after the stock reached a record in July, the company got its first sell rating and shares are now 25% below their peak.“While MRTX849’s clinical profile might ultimately emerge as differentiated relative to Amgen’s AMG 510,” if Amgen achieves a response rate of 50% or better in lung cancer at the higher dose, Mirati’s medicine may face “too high of a bar,” JPMorgan analyst Anupam Rama wrote in an August note.Options data implies Mirati may move 10% between Wednesday and Sept. 20.Meanwhile another heavyweight drugmaker, Johnson & Johnson, has kicked off its’ own study of a KRAS-inhibitor in colon and lung cancers, according to clinicaltrials.gov.\--With assistance from Gregory Calderone and Michelle Fay Cortez.To contact the reporter on this story: Cristin Flanagan in New York at cflanagan1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Steven Fromm, Morwenna ConiamFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
    Reuters

    U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

    The ruling from U.S. District Judge Richard Andrews in Wilmington, Delaware was the latest reversal of fortune in a long-running lawsuit in which Amgen is seeking to stop French drugmaker Sanofi and U.S. biotech Regeneron from selling their drug Praluent. Repatha and Praluent won U.S. approval about two weeks apart in July of 2016.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool

    3 Top Biotech Stocks to Buy Right Now

    Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.

  • Amgen and Celgene’s Otezla Deal: Key Highlights
    Market Realist

    Amgen and Celgene’s Otezla Deal: Key Highlights

    On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.

  • Motley Fool

    What Happened in the Stock Market Today

    Bristol-Myers Squibb and Celgene made a deal to sell a blockbuster drug to Amgen, and Disney and Target are forming a retail collaboration.

  • Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win
    Motley Fool

    Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win

    Here's who wins the most from the sale of Otezla.

  • Companies to Watch: Amgen makes a big deal, Toyota rolls out electric vehicles, Tesla may raise prices in China
    Yahoo Finance

    Companies to Watch: Amgen makes a big deal, Toyota rolls out electric vehicles, Tesla may raise prices in China

    Amgen, Toyota, Tesla, Grab, Disney and Target are the companies to watch.

  • Bloomberg

    Amgen Will Buy Celgene Drug in $13.4 Billion Antitrust Sale

    (Bloomberg) -- Amgen Inc. will pay $13.4 billion for a blockbuster psoriasis drug from Celgene Corp., which is shedding the asset in order to win antitrust regulators’ sign-off for its $74 billion merger with Bristol-Myers Squibb Co.The all-cash deal will give Amgen a growing product at a time when the blockbuster biotechnology drugs it made its name on are beginning to fade. For Celgene and Bristol-Myers, the divestiture will pave the way to one of the pharmaceutical industry’s largest mergers of the past decade.The price is $11.2 billion once future cash tax benefits are taken into account, Thousand Oaks, California-based Amgen said in a statement Monday. Bristol-Myers also expanded a share-buyback plan to $7 billion, from $5 billion.Bristol-Myers has a competing psoriasis drug in development, and in June announced its plan to divest Summit, New Jersey-based Celgene’s Otezla. The psoriasis drug had sales last year of $1.61 billion, and is expected to bring in revenue of $2.71 billion in 2023, according analysts’ estimates compiled by Bloomberg.Shares of Bristol-Myers and Celgene both rose after the announcement: Bristol-Myers rose 3% at 10:30 a.m. in New York trading, and Celgene was up 3.1%. Amgen climbed 3.3%.Antitrust authorities have taken an increasing interest in pharmaceutical deals, which have in the past attracted less scrutiny. Along with the U.S. Federal Trade Commission’s scrutiny of the Celgene deal with Bristol-Myers, the agency is also looking at Roche Holding AG’s planned acquisition of gene therapy company Spark Therapeutics Inc.Antitrust divestitures can present a chance for acquirers to bargain-shop, since the selling companies need to shed the asset to achieve their larger objective. But Celgene and Bristol-Myers may have bucked that trend. Earlier this month, Jefferies analyst Michael Yee said that an $8 billion price would be the benchmark for a cheap price. And in July, Mizuho analyst Salim Syed put a $10 billion high-end price on the drug.The deal is the largest transaction Amgen has attempted in recent memory. The company had one of the largest cash piles in the industry at the end of 2017, stoking speculation that it might use its hoard to buy smaller biotechnology companies. However, last year Amgen spent $10 billion to buy back its own shares rather than pursue a large deal.In an interview Monday, Chief Financial Officer David Meline said Amgen has previously held off on conducting mergers because it viewed potential targets as too expensive.“It’s been quite some time since we’ve done a transaction as it related to business development,” Meline said. “In part, that’s because prices we’ve seen have been too high.”Meline and Murdo Gordon, executive vice president of commercial operations, said Otezla fits well into Amgen’s existing research portfolio. The takeover won’t impede Amgen’s ability to pursue other potential takeovers, Meline said.The deal is contingent on Celgene and Bristol-Myers getting final antitrust approval. Bristol-Myers had previously said it expected the deal to close by the beginning of 2020. On Monday, Bristol-Myers said it now expects the deal to close by the end of this year.Psoriasis is a disease of the immune system, and causes a sometimes-painful rash when it flares up. An estimated 8 million Americans are affected by psoriasis, according to the National Psoriasis Foundation. Otezla is approved for what’s known as plaque psoriasis, the most common form of the disease, as well as psoriatic arthritis.(Updates with comment from Amgen CFO in ninth paragraph. An earlier version of this story corrected the company location to Thousand Oaks.)\--With assistance from Thomas Mulier and Cristin Flanagan.To contact the reporters on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net;Rebecca Spalding in Boston at rspalding@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Mark SchoifetFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion
    Reuters

    Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion

    Amgen, which announced the deal on Monday, is paying a hefty price for the drug, analysts and investors said. Bristol-Myers and Celgene's shares were both up around 3 percent. Bristol-Myers said in June that it would sell Otezla to allay concerns raised by the Federal Trade Commission because of a competing treatment that it is developing.

  • Should Amgen Finally Buy Alexion Pharmaceuticals?
    Motley Fool

    Should Amgen Finally Buy Alexion Pharmaceuticals?

    One of biotech's longest-running buyout rumors is picking up steam again.

  • 3 Reasons Why Amgen Could Actually Acquire Alexion
    Motley Fool

    3 Reasons Why Amgen Could Actually Acquire Alexion

    Rumors that Amgen plans to buy Alexion might not become reality. But a deal would make a lot of sense.

  • Amgen’s Alexion Acquisition: Does It Make Sense?
    Market Realist

    Amgen’s Alexion Acquisition: Does It Make Sense?

    On August 21, Spanish website Intereconomia reported that Amgen would be announcing its acquisition of Alexion Pharmaceuticals in the next few days.

  • Arrowhead Pharmaceuticals: Buy at the High?
    Motley Fool

    Arrowhead Pharmaceuticals: Buy at the High?

    Shares are trading hands at their highest level in years, and have posted a three-year return of over 350%.

  • Is Amgen a Buy?
    Motley Fool

    Is Amgen a Buy?

    The biotech's present and future might not live up to its past.

  • Here's Why Amgen Stock is Outperforming Its Industry Of Late
    Zacks

    Here's Why Amgen Stock is Outperforming Its Industry Of Late

    Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.

  • Mergers & Acquisitions Take Center Stage in Biotech Industry
    Zacks

    Mergers & Acquisitions Take Center Stage in Biotech Industry

    Mergers & Acquisitions Take Center Stage in Biotech Industry

  • Should Value Investors Choose Amgen (AMGN) Stock Now?
    Zacks

    Should Value Investors Choose Amgen (AMGN) Stock Now?

    Let's see if Amgen (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

  • Is Amgen (AMGN) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Amgen (AMGN) Outperforming Other Medical Stocks This Year?

    Is (AMGN) Outperforming Other Medical Stocks This Year?

  • Will Amgen Continue to Surge Higher?
    Zacks

    Will Amgen Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Amgen.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more